World Orphan Drug Congress

World Orphan Drug Congress: Meet Aixial Group in Amsterdam

The World Orphan Drug Congress is the largest and most established rare disease event in the world. This meeting covers the whole orphan drug value chain, from cell and gene therapy to market access. With over 2000 attendees and more than 130 exhibitors, it’s a vital platform for collaboration and innovation.

Our team, including Judit Heiczinger (Director, Strategic Development and Delivery), Nicolas Bouchet (Senior VP, Sales and Business Development), and Aaron De Mello (Senior Director of Business Development), will be at the RAI Congress Centre to discuss how we support advancements in rare diseases. We look forward to engaging in discussions on the latest developments and exploring new opportunities to speed up the delivery of life-changing treatments to patients who need them most.

Aixial has over 20 years’ experience and a deep understanding of the unique challenges of rare disease trials:

• Experience across Phases I–IV, in both adult and pediatric populations
• 20 years: average experience of our team members in clinical trial delivery
• 306 oncology trials, including solid tumours, hematologic malignancies, rare and orphan indications
• 90 indications | Products include assay, Drug (incl. CGIT and radio products), Drug/Device
• Global trial locations across APAC, Europe, LATAM, and North America

Join us at the WODC Europe to learn how Aixial Group can be your reliable partner in accelerating your clinical development.